• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

改变神经酰胺的合成会诱导 PD-L1 的内化和信号转导,从而调节肿瘤转移和免疫治疗反应。

Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response.

机构信息

Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA; Hollings Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.

Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA; Hollings Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA; Department of Surgery, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.

出版信息

Cell Rep. 2024 Aug 27;43(8):114532. doi: 10.1016/j.celrep.2024.114532. Epub 2024 Jul 23.

DOI:10.1016/j.celrep.2024.114532
PMID:39046874
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11404065/
Abstract

Programmed death ligand 1, PD-L1 (CD274), facilitates immune evasion and exerts pro-survival functions in cancer cells. Here, we report a mechanism whereby internalization of PD-L1 in response to alterations of bioactive lipid/ceramide metabolism by ceramide synthase 4 (CerS4) induces sonic hedgehog (Shh) and transforming growth factor β receptor signaling to enhance tumor metastasis in triple-negative breast cancers (TNBCs), exhibiting immunotherapy resistance. Mechanistically, data showed that internalized PD-L1 interacts with an RNA-binding protein, caprin-1, to stabilize Shh/TGFBR1/Wnt mRNAs to induce β-catenin signaling and TNBC growth/metastasis, consistent with increased infiltration of FoxP3 regulatory T cells and resistance to immunotherapy. While mammary tumors developed in MMTV-PyMT/CerS4 were highly metastatic, targeting the Shh/PD-L1 axis using sonidegib and anti-PD-L1 antibody vastly decreased tumor growth and metastasis, consistent with the inhibition of PD-L1 internalization and Shh/Wnt signaling, restoring anti-tumor immune response. These data, validated in clinical samples and databases, provide a mechanism-based therapeutic strategy to improve immunotherapy responses in metastatic TNBCs.

摘要

程序性死亡配体 1(PD-L1,CD274)促进免疫逃逸并在癌细胞中发挥生存促进功能。在这里,我们报告了一种机制,即通过神经酰胺合酶 4(CerS4)对生物活性脂质/神经酰胺代谢的改变,PD-L1 的内化诱导了 Sonic Hedgehog(Shh)和转化生长因子β受体信号,从而增强三阴性乳腺癌(TNBC)的肿瘤转移,表现出免疫治疗抵抗。从机制上讲,数据表明,内化的 PD-L1 与 RNA 结合蛋白 caprin-1 相互作用,以稳定 Shh/TGFBR1/Wnt mRNA,从而诱导β-catenin 信号和 TNBC 的生长/转移,这与 FoxP3 调节性 T 细胞的浸润增加和对免疫治疗的抵抗一致。虽然 MMTV-PyMT/CerS4 中形成的乳腺肿瘤具有高度转移性,但使用 sonidegib 和抗 PD-L1 抗体靶向 Shh/PD-L1 轴可大大降低肿瘤生长和转移,这与 PD-L1 内化和 Shh/Wnt 信号的抑制一致,恢复了抗肿瘤免疫反应。这些在临床样本和数据库中得到验证的数据为改善转移性 TNBC 的免疫治疗反应提供了一种基于机制的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf01/11404065/0b3beefd9391/nihms-2019510-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf01/11404065/c4aadf3dcc35/nihms-2019510-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf01/11404065/ca2fe655f2a6/nihms-2019510-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf01/11404065/9514fbd99f83/nihms-2019510-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf01/11404065/c5cee384e8ed/nihms-2019510-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf01/11404065/cdfe215d1a5b/nihms-2019510-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf01/11404065/eafc94a8938f/nihms-2019510-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf01/11404065/0b3beefd9391/nihms-2019510-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf01/11404065/c4aadf3dcc35/nihms-2019510-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf01/11404065/ca2fe655f2a6/nihms-2019510-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf01/11404065/9514fbd99f83/nihms-2019510-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf01/11404065/c5cee384e8ed/nihms-2019510-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf01/11404065/cdfe215d1a5b/nihms-2019510-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf01/11404065/eafc94a8938f/nihms-2019510-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf01/11404065/0b3beefd9391/nihms-2019510-f0008.jpg

相似文献

1
Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response.改变神经酰胺的合成会诱导 PD-L1 的内化和信号转导,从而调节肿瘤转移和免疫治疗反应。
Cell Rep. 2024 Aug 27;43(8):114532. doi: 10.1016/j.celrep.2024.114532. Epub 2024 Jul 23.
2
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.上皮细胞表达的 B7-H4 驱动了小鼠和人乳腺癌的免疫治疗反应差异。
Cancer Res Commun. 2024 Apr 24;4(4):1120-1134. doi: 10.1158/2767-9764.CRC-23-0468.
3
Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.Syntenin1/MDA-9 (SDCBP) 通过上调 PD-L1 在三阴性乳腺癌中诱导免疫逃逸。
Breast Cancer Res Treat. 2018 Sep;171(2):345-357. doi: 10.1007/s10549-018-4833-8. Epub 2018 May 29.
4
PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer.PD-L1 肿瘤内在信号及其在三阴性乳腺癌中的治疗意义。
JCI Insight. 2021 Apr 22;6(8):131458. doi: 10.1172/jci.insight.131458.
5
ALG3 predicts poor prognosis and increases resistance to anti-PD-1 therapy through modulating PD-L1 N-link glycosylation in TNBC.ALG3 通过调节 TNBC 中 PD-L1 N-连接糖基化来预测不良预后并增加对抗 PD-1 治疗的耐药性。
Int Immunopharmacol. 2024 Oct 25;140:112875. doi: 10.1016/j.intimp.2024.112875. Epub 2024 Aug 9.
6
Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.基于生物纳米颗粒的疫苗和检查点阻断刺激的适应性抗肿瘤免疫反应。
J Exp Clin Cancer Res. 2022 Apr 8;41(1):132. doi: 10.1186/s13046-022-02307-3.
7
WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.WNT 信号通路调节三阴性乳腺癌干细胞区 PD-L1 的表达。
Oncogene. 2019 May;38(21):4047-4060. doi: 10.1038/s41388-019-0700-2. Epub 2019 Jan 31.
8
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.RAS/MAPK激活与三阴性乳腺癌中肿瘤浸润淋巴细胞减少相关:MEK与PD-1/PD-L1免疫检查点抑制剂之间的治疗协同作用
Clin Cancer Res. 2016 Mar 15;22(6):1499-509. doi: 10.1158/1078-0432.CCR-15-1125. Epub 2015 Oct 29.
9
Immunotherapeutic IL-6R and targeting the MCT-1/IL-6/CXCL7/PD-L1 circuit prevent relapse and metastasis of triple-negative breast cancer.免疫治疗 IL-6R 并靶向 MCT-1/IL-6/CXCL7/PD-L1 通路可预防三阴性乳腺癌的复发和转移。
Theranostics. 2024 Mar 3;14(5):2167-2189. doi: 10.7150/thno.92922. eCollection 2024.
10
Disruption of RBMS3 suppresses PD-L1 and enhances antitumor immune activities and therapeutic effects of auranofin against triple-negative breast cancer.RBMS3的破坏会抑制程序性死亡配体1(PD-L1),增强金诺芬对三阴性乳腺癌的抗肿瘤免疫活性和治疗效果。
Chem Biol Interact. 2023 Jan 5;369:110260. doi: 10.1016/j.cbi.2022.110260. Epub 2022 Nov 19.

引用本文的文献

1
Alzheimer's Disease-Associated Amyloid Beta Precursor Protein Prevents Aging Stress-Induced Mitophagy and Fumarate Depletion to Improve Anti-Tumor Immunity.阿尔茨海默病相关淀粉样前体蛋白可预防衰老应激诱导的线粒体自噬和富马酸耗竭,从而改善抗肿瘤免疫。
Cancer Res. 2025 Aug 7. doi: 10.1158/0008-5472.CAN-24-4740.
2
Microbial riboflavin inhibits ceramide synthase 3 to lower ceramide (d18:1/26:0) and delay colorectal cancer progression.微生物核黄素抑制神经酰胺合酶3,以降低神经酰胺(d18:1/26:0)水平并延缓结直肠癌进展。
Cell Metab. 2025 Jun 26. doi: 10.1016/j.cmet.2025.06.002.
3
Ceramide signaling in immunity: a molecular perspective.

本文引用的文献

1
Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies.刺猬信号通路在组织稳态、癌症和靶向治疗中的作用。
Signal Transduct Target Ther. 2023 Aug 18;8(1):315. doi: 10.1038/s41392-023-01559-5.
2
Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950.鉴定膜表达的 CAPRIN-1 为新型通用癌症靶点,并生成治疗性抗 CAPRIN-1 抗体 TRK-950。
Cancer Res Commun. 2023 Apr 18;3(4):640-658. doi: 10.1158/2767-9764.CRC-22-0310. eCollection 2023 Apr.
3
Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment.
免疫中的神经酰胺信号传导:分子视角
Lipids Health Dis. 2025 Jul 1;24(1):225. doi: 10.1186/s12944-025-02642-2.
4
Integrating Single-Cell and Bulk RNA Sequencing Data to Explore Sphingolipid Metabolism Molecular Signatures in Ovarian Cancer Prognosis: an Original Study.整合单细胞和批量RNA测序数据以探索鞘脂代谢分子特征在卵巢癌预后中的作用:一项原创研究
Int J Med Sci. 2025 Mar 24;22(8):1958-1977. doi: 10.7150/ijms.107391. eCollection 2025.
肿瘤 PD-L1 与髓系 PD-1 结合,抑制 I 型干扰素,从而损害细胞毒性 T 淋巴细胞的募集。
Cancer Cell. 2023 Mar 13;41(3):620-636.e9. doi: 10.1016/j.ccell.2023.02.005.
4
Yin and yang regulation of stress granules by Caprin-1.Caprin-1 对应激颗粒的阴阳调控。
Proc Natl Acad Sci U S A. 2022 Nov;119(44):e2207975119. doi: 10.1073/pnas.2207975119. Epub 2022 Oct 24.
5
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.帕博利珠单抗联合化疗治疗晚期三阴性乳腺癌。
N Engl J Med. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809.
6
T-Cell-Specific CerS4 Depletion Prolonged Inflammation and Enhanced Tumor Burden in the AOM/DSS-Induced CAC Model.T 细胞特异性 CerS4 耗竭延长了 AOM/DSS 诱导的 CAC 模型中的炎症和增强肿瘤负担。
Int J Mol Sci. 2022 Feb 7;23(3):1866. doi: 10.3390/ijms23031866.
7
PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-β receptor I versus II.PD-L1 通过选择性针对 TGF-β 受体 I 与 II 的不同机制促进肝星状细胞的肌成纤维细胞激活。
Cell Rep. 2022 Feb 8;38(6):110349. doi: 10.1016/j.celrep.2022.110349.
8
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics.癌症中调节程序性死亡受体配体1(PD-L1)表达的机制及新型小分子疗法的相关机遇
Nat Rev Clin Oncol. 2022 May;19(5):287-305. doi: 10.1038/s41571-022-00601-9. Epub 2022 Feb 7.
9
Prognostic Role of PD-L1 Expression in Invasive Breast Cancer: A Systematic Review and Meta-Analysis.程序性死亡配体1(PD-L1)表达在浸润性乳腺癌中的预后作用:一项系统评价和荟萃分析
Cancers (Basel). 2021 Dec 3;13(23):6090. doi: 10.3390/cancers13236090.
10
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.IMpassion131 研究是一项双盲、安慰剂对照、随机 III 期临床试验,旨在评估一线紫杉醇联合或不联合阿替利珠单抗治疗不可切除局部晚期/转移性三阴性乳腺癌的主要结果。
Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1.